They don't have anything to prove I guess. Or maybe another stupid huge buyout by a big company of this useless ad network, and that's why no PR.
I did forget to mention BARDA, but don't see any positive surprises in the short term on it.
I did mention Japan though.
I kind of mentioned China. (Lorem Vascular)
Wonder what happened to our old pal ceeing. Maybe new ID.
I've been following PPHM on and off ever since the independent trial result mix-up/fiasco. Would you say PPHM's drug line-up is more than marginal at present? In other words does it actually massively improve odds for specific cancers or is it like a "2 month extension" of life?
Well, a quick recap.
* Cytori gets stem cells from fat with a centrifuge-like device. It is called a CTX-1 I believe, and very expensive. They need money to finish development of CTX-2, which is much cheaper to produce/use.
* Lots of uninformed momentum buyers piling in today. Even saw a "let's cure cancer!" comment. (?!?!)
* The science is good and has multiple indications. The initial trials for the sceloderma indication gave fantastic results last year. Now they have an FDA-sponsored trial in the US. The knee injury indication also has good results, per Dr. Cugat, a Spanish doctor specializing in treatment of sports players with knee injuries. Cardiac is an unknown at this point, however. Then there are some others, like urinary incontinence in Japan and osteo-arthritis trials.
* A handful of partnerships (Lorem Vascular, Okyanos) but they are moving slowly and/or not making an earth-shattering amount of revenue.
* With the scleroderma FDA-sponsored trial, clear path to market in the US market. With the European market: orphan drug designation positive recommendation. With Japan, they have new laws that make it easier for new drugs to come to market faster and make "device companies" like Cytori more competitive versus non-device companies.
* Cytori has been in a cash crunch situation for years. That's why they hit a low of as little as .36 or .38 late October. Typical problems of inept management, nepotism, firing experienced researchers and hiring interns for years. They did change the CEO and the CFO a few months ago. The "new" CEO is one of the chief medical officers. The CFO is a new hire and doing good work with reigning in the financial incompetence of the old regime.
* Warrants/convertibles: Sabby Management and a few instutional players with smaller stakes can own 40% of the company with .52 bond/share convertibles and .57 warrants coming online in the summer.